Helix BioMedix Reports 2006 Financial Results
BOTHELL, Wash., March 27 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. (BULLETIN BOARD: HXBM.OB) , a developer of bioactive peptides, today announced financial results for the year ended December 31, 2006.
For 2006, Helix BioMedix reported a net loss of $3,828,326, or $0.17 net loss per share, compared to a net loss of $3,277,239, or $0.18 net loss per share, for 2005. The 2006 results include approximately $391,200 of incremental expense for stock-based compensation due to the adoption of SFAS 123R "Share Based Payment" during the first quarter of 2006. .
No comments:
Post a Comment